U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare sector ...

Dubai Bain Capital is in the final stages of negotiations to acquire Mitsubishi Chemical Group's pharmaceutical subs ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.